Results 191 to 200 of about 29,583 (248)

DCIS and aromatase inhibitors

The Journal of Steroid Biochemistry and Molecular Biology, 2007
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon, Dana, Faratian, Sharon, White, Lorna, Renshaw, Juliette, Murray, Oliver, Young, E Jane, Macaskill, Linda, Williams, Jeremy, Thomas, Dean B, Evans   +9 more
openaire   +2 more sources

Abstract P3-14-03: Differences in pathological and biological factors between DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC).

Cancer Research, 2012
Abstract Background: Specific pathological and biological factors differentiating pure DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC) are currently unknown. Identification of such factors would enable us to better understand the transition from an in situ to an invasive carcinoma ...
G MacGrogan, MC Baranzelli, JM Picquenot, F Penault-Llorca, MC Mathieu, P Tas, V Fermeaux, E Mery, C Sagan, C Blanc-Fournier, E Brabencova, L Arnould, J Jacquemier, F Ettore, V Velasco, B Gonzalves, V Brouste, de Lara C Tunon   +17 more
openaire   +1 more source

Experiences with DCI Pattern

2015
The DCI architectural pattern for software, introduced by Reenskaug, contains three parts: Data, Context and Interaction. Data represent domain knowledge while Context and Interaction represent the business logic by implementing communication between objects. Context dynamically injects roles into objects.
Ilona Bluemke, Anna Stepien
openaire   +2 more sources

Pro: SLNB in DCIS

Annals of Surgical Oncology, 2006
The role of sentinel node mapping and biopsy in the management of ductal carcinoma in situ (DCIS) remains controversial. A debate about the use of a staging technique for the evaluation of a malignancy without metastatic potential seems absurd. However, this debate is fueled by two factors. First, some patients diagnosed with DCIS will ultimately prove
openaire   +2 more sources

Different Distribution of Breast Cancer Subtypes in Breast Ductal Carcinoma in situ (DCIS), DCIS with Microinvasion, and DCIS with Invasion Component

Annals of Surgical Oncology, 2010
Breast ductal carcinoma in situ with microinvasion (DCIS-Mi) is considered to be the interim stage in the progression from DCIS to invasive breast cancer (IDC). Cases that exceed DCIS-Mi but still do not fulfill the diagnostic criteria of IDC often are observed.
Ke-Da, Yu, La-Mu, Wu, Guang-Yu, Liu, Jiong, Wu, Gen-Hong, Di, Zhen-Zhou, Shen, Zhi-Ming, Shao   +6 more
openaire   +2 more sources

Zbrinjavanje DCIS

2023
U predavanju je obuhvaćeno povijesno i sadašnje zbrinjavanje duktalnog karcinoma in situ, prikazani su rezultati Klinike za tumore u liječenju DCIS, uključujući učestalost recidiva nakon 10-15 godina. Također, prikazani su trendovi budućeg liječenja ove bolesti, kao i prospektivne studije koje su u tijeku, a istražuju aktivno praćenje DCIS ...
Stanec, Mladen, Milas, Ivan, Guteša, Ilija   +2 more
openaire  

Current Therapeutic Approaches to DCIS

Journal of Mammary Gland Biology and Neoplasia, 2018
Treatment for ductal carcinoma in-situ (DCIS) has historically been extrapolated from studies of invasive breast cancer. Accepted local therapy approaches range from small local excisions, with or without radiation, to bilateral mastectomies. Systemic treatment with endocrine therapy is often recommended for hormone positive patients. With improvements
Kaleigh Doke, Shirley Butler, Melissa P. Mitchell   +2 more
openaire   +2 more sources

Is DCIS Overrated?

2018
Ductal carcinoma in situ (DCIS), the noninvasive form of breast cancer (BC), comprises just over 20% of breast cancer cases diagnosed each year in the USA. Most patients are treated with local excision of the disease followed by whole breast radiation therapy.
Joshua, Feinberg, Rachel, Wetstone, Dana, Greenstein, Patrick, Borgen   +3 more
openaire   +2 more sources

The Impact of MRI on the Treatment of DCIS

The American Surgeon™, 2005
Magnetic resonance imaging (MRI) has been shown to detect occult invasive breast cancers with a sensitivity of 97 per cent to 100 per cent. Mammography and ultrasonography does not accurately assess the extent of ductal carcinoma in situ (DCIS), which results in a high reoperation rate.
Alice, Chung, Rola, Saouaf, Karen, Scharre, Edward, Phillips   +3 more
openaire   +2 more sources

The defence for the U.K. DCIS trial

European Journal of Cancer, 1993
INTRODUCTION THE U.K. ductal carcinoma in siru (DCIS) trial started in May 1991, after a gestation period of 36 months, having been designed by a multidisciplinary committee. This comprised clinicians with a particular interest in DCIS and included surgeons, radiotherapists, pathologists, statisticians and data centre coordinators. The aim of the study
I S, Fentiman, C A, Joslin
openaire   +2 more sources